Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05780541 · ClinicalTrials.gov registry record · Phase 3
PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
A Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Phase 3
- Development phase
- 58
- Enrollment target
NCT05780541 is a Phase 3 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 58 participants.
The verdict
NCT05780541, a Phase 3 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 58 participants
- Enrollment target
Study Summary
This study looks at the safety and effectiveness of PF-07304814 in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either PF-07304814 plus current standard of care (SOC), or with placebo plus current SOC. This is ACTIV-3/TICO Treatment Trial H6.
Interventions
- DRUG Placebo
- BIOLOGICAL Remdesivir
- DRUG PF-07304814
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2021-09-15 |
| Est. Completion | 2023-07-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05780541
The ClinicalTrials.gov registry entry for NCT05780541 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05780541 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05780541 about?
NCT05780541 is a clinical study titled "PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)". This study looks at the safety and effectiveness of PF-07304814 in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either PF-07304814 plus current standard of care (SOC), or with placebo plus current SOC. This is ACTIV-3/TICO ...
What is the current status of trial NCT05780541?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 58 participants. The study started on 2021-09-15. Estimated completion is 2023-07-14.
What interventions are being tested in trial NCT05780541?
The interventions under investigation include: Placebo (DRUG), Remdesivir (BIOLOGICAL), PF-07304814 (DRUG).
Who is sponsoring clinical trial NCT05780541?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.